Geron Co. (GERN) Receives Consensus Rating of “Hold” from Analysts

Geron Co. (NASDAQ:GERN) has earned a consensus rating of “Hold” from the six research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $3.75.

A number of brokerages have recently weighed in on GERN. Zacks Investment Research downgraded shares of Geron from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. Needham & Company LLC reaffirmed a “hold” rating on shares of Geron in a report on Friday, November 3rd. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a $2.50 price target on shares of Geron in a report on Friday, November 3rd.

Shares of Geron (GERN) opened at $1.87 on Friday. Geron has a twelve month low of $1.74 and a twelve month high of $3.15.

Geron (NASDAQ:GERN) last posted its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.01. The firm had revenue of $0.16 million during the quarter, compared to the consensus estimate of $0.40 million. Geron had a negative net margin of 2,992.67% and a negative return on equity of 25.14%. The business’s revenue for the quarter was down 96.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.02) EPS. equities analysts forecast that Geron will post -0.17 earnings per share for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Geron by 4.1% during the 2nd quarter. Vanguard Group Inc. now owns 7,406,968 shares of the biopharmaceutical company’s stock worth $20,518,000 after purchasing an additional 294,785 shares in the last quarter. State Street Corp increased its position in Geron by 9.8% during the 2nd quarter. State Street Corp now owns 5,127,578 shares of the biopharmaceutical company’s stock worth $14,205,000 after purchasing an additional 459,700 shares in the last quarter. Raymond James Financial Services Advisors Inc. increased its position in Geron by 42.0% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 82,426 shares of the biopharmaceutical company’s stock worth $180,000 after purchasing an additional 24,370 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in Geron during the 2nd quarter worth approximately $114,000. Finally, Wells Fargo & Company MN increased its position in Geron by 13.7% during the 2nd quarter. Wells Fargo & Company MN now owns 122,838 shares of the biopharmaceutical company’s stock worth $341,000 after purchasing an additional 14,800 shares in the last quarter. Institutional investors and hedge funds own 39.21% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Geron Co. (GERN) Receives Consensus Rating of “Hold” from Analysts” was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://www.com-unik.info/2017/12/22/geron-co-gern-receives-consensus-rating-of-hold-from-analysts.html.

Geron Company Profile

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.

What are top analysts saying about Geron? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Geron and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit